A topical thermosensitive hydrogel system with cyclosporine A PEG-PCL micelles alleviates ulcerative colitis induced by TNBS in mice

Xiao, Chuyao; Li, Genyun; Li, Xiaoyue; Wang, Dan; Wu, Ya; Sun, Minghui; Huang, Jiangeng; Si, Luqin

doi:10.1007/s13346-023-01317-8

Cited by 3 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To decrease the adverse effects of therapeutics, several smart responsive nanoplatforms were developed to deliver therapeutics for the targeted treatment of colitis. For example, glutathione-, pH- or thermoresponsive nanoplatforms were used to load methotrexate, cyclosporine A (CsA), , recombinant human lactoferrin, and procyanidin for alleviation of colitis, respectively. In addition, pH/ROS and pH/glutathione dual responsive delivery systems were also employed to deliver astaxanthin, curcumin, and ginsenoside for the targeted treatment of IBD.…”

Section: Introductionmentioning

confidence: 99%

Cyclosporine A-Encapsulated pH/ROS Dual-Responsive Nanoformulations for the Targeted Treatment of Colitis in Mice

Li,

Wu,

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a frequently occurring disease that seriously influences the patient’s quality of life. To decrease adverse effects and improve efficacy of therapeutics, nanomedicines have been widely used to treat IBD. However, how to thoroughly release payloads under an inflammatory microenvironment and synergistic therapy of IBD need to be further investigated. To address this issue, cyclosporine A (CsA)-loaded, folic acid (FA)-modified, pH and reactive oxygen species (ROS) dual-responsive nanoparticles (FA-CsA NPs) were fabricated using pH/ROS-responsive material as carrier. The prepared FA-CsA NPs had spherical shape and uniform size distribution and could smartly release their payloads under acid and/or ROS microenvironment. In vitro experiments demonstrated that FA-CsA NPs can be effectively internalized by activated macrophages, and the internalized NPs could down-regulate the expression of proinflammatory cytokines compared to free drug or nontargeted NPs. In vivo experiments verified that FA-CsA NPs significantly accumulated at inflammatory colon tissues and the accumulated NPs obviously improved the symptoms of colitis in mice without obvious adverse effects. In conclusion, our results provided a candidate for the targeted treatment of IBD.

show abstract

Section: Introductionmentioning

confidence: 99%

Cyclosporine A-Encapsulated pH/ROS Dual-Responsive Nanoformulations for the Targeted Treatment of Colitis in Mice

Li,

Wu,

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

Propelling Minimally Invasive Tissue Regeneration With Next‐Era Injectable Pre‐Formed Scaffolds

Liao,

Timoshenko,

Cordova

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

The growing aging population, with its associated chronic diseases, underscores the urgency for effective tissue regeneration strategies. Biomaterials have played a pivotal role in the realm of tissue reconstruction and regeneration, with a distinct shift towards minimally invasive (MI) treatments. This transition, fueled by engineered biomaterials, has steered away from invasive surgical procedures to embrace approaches offering reduced trauma, accelerated recovery, and cost‐effectiveness. In the realm of MI tissue repair and cargo delivery, various techniques have been explored. While in situ polymerization has been prominent, it is not without its challenges. This narrative review explores diverse biomaterials, fabrication methods, and biofunctionalization for injectable pre‐formed scaffolds, focusing on their unique advantages. The injectable pre‐formed scaffolds, exhibiting compressibility, controlled injection, and maintained mechanical integrity, emerge as promising alternative solutions to in situ polymerization challenges. The conclusion of this review emphasizes the importance of interdisciplinary design facilitated by synergizing fields of materials science, advanced 3D biomanufacturing, and mechanobiological studies, and innovative approaches for effective MI tissue regeneration.This article is protected by copyright. All rights reserved

show abstract

De Novo Inflammatory Bowel Disease after Liver Transplantation: Eleven Years' Experience in Shiraz, Iran

Paridar,

Kassani

2024

J Adv Immunopharmacol

View full text Add to dashboard Cite

Background: Inflammation may occur after solid and liquid liver transplantations at a rate higher than in the general population. Objectives: This study aimed to investigate the incidence of de novo inflammatory bowel disease (IBD) and assess some risk factors after Orthotopic liver transplantation (OLT) in liver transplant patients in Shiraz, Iran. Methods: The sample study comprised patients (n = 1702) who had received liver transplants between 2001 and 2012 at the Shiraz liver transplant center. The data were obtained from patient records, which included information on their medical history, colonoscopy reports, family history of IBD, and other risk factors. The study evaluated the status of inflammatory bowel disease (IBD) among patients who had undergone liver transplantations due to autoimmune hepatitis group (AIH), Primary Sclerosing Cholangitis (PSC), and other liver transplant patients. Additionally, case groups were formed, comprising AIH patients (n1 = 10) and other patients with IBD (n2 = 10), and were compared with transplant patients without IBD as the control group (n1 = 21, n2 = 21). Results: Out of the total 1702 patients, 254 (14.92%) had AIH, 211 (12.40%) had PSC, and 1237 (72.68%) had other outcomes. The mean of leukocyte counts (P-value = 0.73), types of immunosuppressant medications, and serum levels of cyclosporine (P-value = 0.77) and tacrolimus (P-value = 0.27) did not show any significant differences between the case and control groups. However, it was observed that IBD developed earlier in patients with AIH compared to other patients (20.1 ± 2.23 vs 53.9 ± 4.42 months). Conclusions: The incidence of IBD after liver transplantation was higher compared to the general population, and it occurred earlier in patients who underwent transplantation for AIH and other groups.

show abstract

A topical thermosensitive hydrogel system with cyclosporine A PEG-PCL micelles alleviates ulcerative colitis induced by TNBS in mice

Cited by 3 publications

References 62 publications

Cyclosporine A-Encapsulated pH/ROS Dual-Responsive Nanoformulations for the Targeted Treatment of Colitis in Mice

Cyclosporine A-Encapsulated pH/ROS Dual-Responsive Nanoformulations for the Targeted Treatment of Colitis in Mice

Propelling Minimally Invasive Tissue Regeneration With Next‐Era Injectable Pre‐Formed Scaffolds

De Novo Inflammatory Bowel Disease after Liver Transplantation: Eleven Years' Experience in Shiraz, Iran

Contact Info

Product

Resources

About